Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Sprott Uranium Miners ETF — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Sprott Uranium Miners ETF trades at $42.19 (market cap $1.78B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 2.7× Sprott Uranium Miners ETF's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Sprott Uranium Miners ETF for 62 Days on average.
| TVTX | URNM | |
|---|---|---|
Market Cap | $4.88B | $1.78B |
Volume | 1,668,577 | 1,008,269 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $67.52 | $83.99 |
52-Week Low | $26.79 | $42.42 |
Typical Hold Time | 0 Days | 62 Days |
Enterprise Value | $5.01B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
URNM trades at $44.51, down 1.44% on the day, with a bearish technical signal from moving averages and oscillators. Recent news highlights uranium's role in AI energy demand and nuclear expansion, but financial ratios are unavailable. The ETF tracks uranium miners, with support at $43 and resistance at $46.
Long-term prospects are supported by nuclear energy growth and AI power needs, but short-term price volatility and lack of fundamental data pose risks. Investor sentiment is mixed, with bullish articles on uranium's future but technical indicators suggesting caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
